Showing 1801-1810 of 2105 results for "".
- The FDA Approves a Once-Daily Medication for Treating Hyperphagia Caused by Prader-Willi Syndromehttps://practicalneurology.com/news/the-fda-approves-a-once-daily-medication-for-treating-hyperphagia-caused-by-prader-willi-syndrome/2473822/The Food and Drug Administration (FDA) has approved Vykat XR (diazoxide choline [DCCR] extended-release tablets; Soleno, Redwood City, CA) for the treatment of hyperphagia in people with Prader-Willi syndrome (PWS) aged 4 years and older. Vykat XR is an extended-release formulation of DCCR, a cry
- Soliris Now Approved to Treat Children with Generalized Myasthenia Gravishttps://practicalneurology.com/news/soliris-now-approved-to-treat-children-with-generalized-myasthenia-gravis/2473804/The Food and Drug Administration (FDA) has approved the expansion of the indication of Soliris (eculizumab; Alexion Pharmaceuticals, Boston, MA) to now include treatment for pediatric patients aged ≥6 years with anti-acetylcholine receptor (AChR) antibody positive generalized myasthenia gravis
- FDA Approves Tenecteplase Treatment for Acute Ischemic Strokehttps://practicalneurology.com/news/fda-approves-tenecteplase-treatment-for-acute-ischemic-stroke/2473803/TNKase (Tenecteplase; Genentech, South San Francisco, CA) has received approval from the Food and Drug Administration (FDA) for the treatment of adults with acute ischemic stroke. TNKase is a tissue plasminogen activator, thrombolytic agent that is administered as a single 5-second intravenous (I
- Radiprodil Designated a Breakthrough Therapy for GRIN-Related Neurodevelopmental Disorderhttps://practicalneurology.com/news/radiprodil-designated-a-breakthrough-therapy-for-grin-related-neurodevelopmental-disorder/2473793/Radiprodil (GRIN Therapeutics, New York, NY), a selective, potent negative allosteric modulator of the N-methyl-D-aspartate receptor subtype SB (NR2B or GluN2B), has been granted Breakthrough Therapy designation by the Food and Drug Administration (FDA) for the treatment of seizures associated wi
- New Tablet Formulation of Evrysdi for Spinal Muscular Atrophy Greenlighted by the FDAhttps://practicalneurology.com/news/new-tablet-formulation-of-evrysdi-for-spinal-muscular-atrophy-greenlighted-by-the-fda/2473784/A New Drug Application (NDA) for a tablet formulation of Evrysdi (risdiplam; Genentech, South San Francisco, CA) has been approved by the Food and Drug Administration (FDA) for the treatment of participants aged ≥2 years with spinal muscular atrophy (SMA) who weigh ≥20 kg. Evrysdi was first
- Anaphylaxis Boxed Warning Added to MS Medication Labelhttps://practicalneurology.com/news/anaphylaxis-boxed-warning-added-to-ms-medication-label/2473770/The Food and Drug Administration (FDA) has added a Boxed Warning to the prescribing information of glatiramer acetate, a medication for multiple sclerosis (MS) sold under the brand name Copaxone (glatiramer acetate injection; Teva, Tel Aviv-Yafo, Israel) and the generic name Glatopa (glatiramer a
- Hypertensive Pregnancies Linked to Increased Risk of Neurologic Conditionshttps://practicalneurology.com/news/hypertensive-pregnancies-linked-to-increased-risk-of-neurological-conditions/2470945/A Swedish register-based cohort study, published in JAMA Neurology, has found that women who experience gestational hypertension, preeclampsia, or eclampsia during pregnancy face an elevated risk of developing neurologic disorders in the months to years following childbirth, including mi
- Warning for Guillain-Barré Syndrome Added to the Labels of 2 RSV Vaccineshttps://practicalneurology.com/news/warning-for-guillain-barre-syndrome-added-to-the-labels-of-2-rsv-vaccines/2470942/The prescribing information for the vaccines Abrysvo (respiratory syncytial virus vaccine; Pfizer, New York, NY) and Arexvy (respiratory syncytial virus vaccine, adjuvanted; GSK, London, United Kingdom) has been updated to include new warnings for the risk of Guillain-Barré syndrome (GBS).
- Frailty Linked to Greater Risk of Dementiahttps://practicalneurology.com/news/frailty-linked-to-greater-risk-of-dementia/2470643/Frailty measurements may enable the identification of individuals at higher risk of dementia up to 9 years before the onset of the disorder, according to study results published in JAMA Neurology. According to the study authors, the findings demonstrate the potential utility of frailty m
- Children with Migraine Can Now Receive Neuromodulatory Treatment with the Nerivio REN Devicehttps://practicalneurology.com/news/children-with-migraine-can-now-receive-neuromodulatory-treatment-with-the-nerivio-device-1/2470639/The Food and Drug Administration (FDA) has expanded the age indication for Nerivio (Theranica, Bridgewater Township, NJ), making it the first non-drug therapy and prescribed preventive treatment for children with migraine aged ≥8 years. Nerivio is a remote electrical neuromodulation (REN) devi